Bruce Connop, Ph.D., Vice President, Toxicology, Strategy, & Development, Pharmaceuticals & Healthcare
Bruce Connop is a seasoned drug development executive with over 25 yrs of Biotech and Pharmaceutical experience. He has a proven record of success at various stages of drug development through to BLA/NDA approval.
Bruce is a Subject Matter Lead for non-clinical development and clinical pharmacology programs to support clinical advancement through to commercialization. He also has an extensive experience with large Pharma partnerships for over 10 years (Lilly and Pfizer; Subject Matter Lead). Development of Ngenla™ (long-acting human growth hormone) with Pfizer.
While he is proficient in translating scientific results into commercial value resulting in high levels of responsibility, Bruce also has exceptional organizational and communication skills. He is known for how he advances objectives through effective management of internal teams as well as contract research organizations and external collaborations.
He is a leader with scientific expertise in many areas of drug development; analytical methods, formulation development, DMPK, regulatory toxicology, clinical immunogenicity and bioanalytics/pharmacokinetics. Bruce is also a Member of Senior Joint Development Committees with Pharma collaborators (Lilly, Novo Nordisk, Pfizer, etc.) as well as Subject Matter Lead for Manufacturing (early phase), Non-clinical Development and Clinical Pharmacology through to BLA/NDA.
